Peculiarities of acute gouty arthritis treatment in patients with concomitant pathology. Part 1: main limitations and adverse effects of medicamentous therapy

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Acute gouty arthritis is characterized by expressed inflammatory symptoms and severe pain syndrome, requiring immediate medical relief. Article discusses the general points of anti-inflammatory medicines (non-steroidal anti-inflammatory drugs, glucocorticosteroids, colchicine) use acute gouty arthritis treatment against the background of associated risks in comorbid patients.

Full Text

Restricted Access

About the authors

Vera V. Lyalina

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Author for correspondence.
Email: vera_lyalina@mail.ru
ORCID iD: 0000-0002-4262-4060

PhD in Medical Sciences, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.

Elina A. Skripnichenko

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia; V.M. Buyanov City Clinical Hospital of the Department of Healthcare of Moscow

Email: elkaskrip@gmail.com
ORCID iD: 0000-0001-6321-8419

postgraduate student of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.; Moscow

Svetlana V. Borisovskaya

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia; V.M. Buyanov City Clinical Hospital of the Department of Healthcare of Moscow

Email: svabor@inbox.ru
ORCID iD: 0000-0002-9365-1472

PhD in Medical Sciences, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.; Moscow

Ruslan N. Obyedkov

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: rn.obedkov98@gmail.com
ORCID iD: 0000-0002-8689-6623

student of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.

Igor G. Nikitin

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881

MD, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, director

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.

References

  1. Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004; 42(1): 5–7. [Nasonova V. A., Barskova V. G. Early diagnosis and treatment of gout is a scientifically based requirement for improving the work and life prognosis of patients. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology. 2004; 42(1): 5–7. EDN: QCWYZP.
  2. Дженсон Р. У. Подагра. В кн.: Секреты ревматологии. Под. ред. Стерлинга Дж. Уэста (пер. с англ. под ред. О.М. Лесняк). М.: ГЭОТАР-Медиа. 2018; с. 359–367. [Jenson R.W. Gout. In: Rheumatology secrets. Ed. by Sterling J. West (translation from English edited by O.M. Lesnyak). Moscow: GEOTAR-Media. 2018; pp. 359–367 (In Russ.)]. ISBN: 978-5-9704-4508-2.
  3. MSD Manual. Keller S.F. Gout. 2022. URL: https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/crystal-induced-arthritides/gout (date of access – 01.02.2023).
  4. Medscape. Rothschild B.M. Gout and pseudogout. 2020 (Updated: Jan 11, 2023). URL: https://emedicine.medscape.com/article/329958-overview (date of access – 01.02.2023).
  5. Клинические рекомендации. Подагра. Ассоциация ревматологов России. 2018. ID: 251. Доступ: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/ (дата обращения – 01.01.2023). [Clinical guidelines. Gout. Association of Rheumatologists of Russia. 2018. ID: 251. URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/ (date of access – 01.01.2023).
  6. Pillinger M.H., Mandell B.F. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020; 50(3S): S24–S30. https://dx.doi.org/10.1016/j.semarthrit.2020.04.010.
  7. Gow P. Treating gout in patients with comorbidities. Int J Clin Rheumtol. 2011; 6(6): 625–33. https://dx.doi.org/10.2217/ijr.11.63.
  8. UpToDate. Gaffo A.L. Treatment of gout flares. 2022. URL: https://www.uptodate.com/contents/treatment-of-gout-flares (date of access – 01.01.2023).
  9. Елисеев М.С., Насонов Е.Л. Применение канакинумаба при подагре. Научно-практическая ревматология. 2018; 56(S4): 41–48. [Eliseev MS, Nasonov EL. Therapy with canakinumab for gout. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology. 2018; 56(S4): 41–48 (In Russ.)]. https://dx.doi.org/10.14412/1995-4484-2018-41-48.
  10. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(S1): 1–29. [Karateev A. E., Nasonov E. L., Ivashkin V. T. et al. Rational use of non-steroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology. 2018; 56(S1): 1–29 (In Russ.)]. https://dx.doi.org/10.14412/1995-4484-2018-1-29. EDN: PCPKRP.
  11. Yu T.F., Gutman A.B. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959; 38(8): 1298–315. https://dx.doi.org/10.1172/JCI103905.
  12. Фингер Д.Р. Гипоурикемические средства и колхицин. В кн.: Секреты ревматологии. Под. ред. Стерлинга Дж. Уэста (пер. с англ. под ред. О.М. Лесняк). М.: ГЭОТАР-Медиа. 2018; с. 683–690. [Finger D.R. Hypouricemic drugs and colchicine. In: Rheumatology secrets. Ed. by Sterling J. West (translation from English edited by O.M. Lesnyak). Moscow: GEOTAR-Media. 2018; pp. 683–690 (In Russ.)]. ISBN: 978-5-9704-4508-2.
  13. Terkeltaub R.A., Furst D.E., DiGiacinto J.L. et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011; 63(8): 2226–37. https://dx.doi.org/10.1002/art.30389.
  14. FDA. Drug development and drug interactions. Table of substrates, inhibitors and inducers. 2022. URL: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers (date of access – 01.01.2023).
  15. Читкара П., Деннис Г.Д. Глюкокортикоиды – системные и местные. В кн.: Секреты ревматологии. Под. ред. Стерлинга Дж. Уэста (пер. с англ. под ред. О.М. Лесняк). М.: ГЭОТАР-Медиа. 2018; с. 644–651. [Chitkara P., Dennis G.D. Glucocorticoids – systemic and local. In: Rheumatology secrets. Ed. by Sterling J. West (translation from English edited by O.M. Lesnyak). Moscow: GEOTAR-Media. 2018; pp. 644–651 (In Russ.)]. ISBN: 978-5-9704-4508-2.
  16. Stamp L.K., Chapman P.T. Gout and its comorbidities: Implications for therapy. Rheumatology (Oxford). 2013; 52(1): 34–44. https://dx.doi.org/10.1093/rheumatology/kes211.
  17. Schumacher H.R. Aspiration and injection therapies for joints. Arthritis Rheum. 2003; 49(3): 413–20. https://dx.doi.org/10.1002/art.11056.
  18. van Tuyl S.A.C., Slee P.H.T.J. Are the effects of local treatment with glucocorticoids only local? Neth J Med. 2002; 60(3): 130–32.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies